Characterizing protein function and protective antibody levels to the leading P. vivax malaria vaccine candidate MSP3

Chief Investigator:

Dr Danny Wilson

Funding Amount:



University of Adelaide


P. vivax causes ~80 million malaria cases annually, with children in Australia’s neighbouring countries badly affected. In a major collaboration between the Menzies Institute and University of Adelaide, we will develop a unique model of P. vivax vaccine candidate PvMSP3. Using this model, we will detail the unknown function of PvMSP3 and quantify the immune response targeting PvMSP3 that protects children from disease. This study will assess PvMSP3 vaccine candidacy and provide innovative tools to shorten the timeframe of vaccine development against this debilitating childhood pathogen.

Leave a Reply